Your shopping cart is currently empty

HFI-142 is a small-molecule inhibitor that binds specifically to the active site of aminopeptidase N and suppresses its enzymatic activity. HFI-142 has been demonstrated to inhibit leukotriene A4 biosynthesis in red blood cells, an effect that may offer therapeutic potential for the research in cancer by modulating inflammatory and metabolic pathways implicated in tumor growth and progression. HFI-142 was also shown to inhibit the activity of additional aminopeptidases, including aminopeptidase N, as well as other enzymes associated with protein metabolism.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $59 | - | In Stock | |
| 5 mg | $128 | 5 days | 5 days | |
| 1 mL x 10 mM (in DMSO) | $189 | 5 days | 5 days |
| Description | HFI-142 is a small-molecule inhibitor that binds specifically to the active site of aminopeptidase N and suppresses its enzymatic activity. HFI-142 has been demonstrated to inhibit leukotriene A4 biosynthesis in red blood cells, an effect that may offer therapeutic potential for the research in cancer by modulating inflammatory and metabolic pathways implicated in tumor growth and progression. HFI-142 was also shown to inhibit the activity of additional aminopeptidases, including aminopeptidase N, as well as other enzymes associated with protein metabolism. |
| Targets&IC50 | IRAP:2.01 μM (ki) |
| Molecular Weight | 312.32 |
| Formula | C17H16N2O4 |
| Cas No. | 332164-34-8 |
| Smiles | O=C(OCC)C1=C(OC2=CC(O)=CC=C2C1C=3C=NC=CC3)N |
| Relative Density. | 1.334 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (320.18 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (12.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.